Abstract:Key Points Question To what extent do global polygenic risk scores (PRS), molecular pathway-specific PRS, complement component (C4) gene expression, MHC loci, sex, and ancestry jointly contribute to risk for schizophrenia-spectrum disorders (SZ)? Findings Global polygenic risk for schizophrenia, sex, and their interaction most robustly predict risk in a classification and regression tree model, with highest risk groups having 50/50 chance of SZ. Meaning Psychometric risk indicators, such as prodromal symptom assessments, may be enhanced by the examination of genetic risk metrics. Preliminary results suggest that of genetic risk metrics, global polygenic information has the most potential to significantly aide in the prediction of SZ. Abstract Importance Schizophrenia (SZ) has a complex, heterogeneous symptom presentation with limited established associations between biological markers and illness onset. Many (gene) molecular pathways (MPs) are enriched for SZ signal, but it is still unclear how these MPs, global PRS, major histocompatibility complex (MHC) complement component (C4) gene expression, and MHC loci might jointly contribute to SZ and its clinical presentation. It is also unclear whether sex or ancestry interacts with these metrics to increase risk in certain individuals. Objective To examine multiple genetic metrics, sex, and their interactions as possible predictors of SZ risk. Genetic information could aid in the clinical prediction of risk, but it is still unclear which genetic metrics are most promising, and how sex interacts with genetic risk metrics. Design, Setting, and Participants To examine molecular risk in a proof-of-concept study, we used the Wellcome Trust case-control cohort and classified cases as a function of 1) polygenic risk score (PRS) for both whole genome and for 345 implicated molecular pathways, 2) predicted C4 expression, 3) SZ-relevant MHC loci, 4) sex, and 5) ancestry. Main Outcomes and Measures PRSs, C4 expression, SZ-relevant MHC loci, sex, and ancestry as joint risk factors for SZ. Results Recursive partitioning yielded 15 molecular risk classes and retained as significant psychosis classifiers only sex, genome-wide SZ polygenic risk, and one MP PRS. Sex was the most robust classifier in a stepwise regression, and there was a significant interaction of sex with SZ PRS on case status, suggesting males have a lower polygenic risk threshold. By down-sampling case proportion to 1% and 1.4% population base rates in males and females, respectively, high-risk subtypes defined by this model had roughly a 52% odds of developing SZ (individuals with SZ PRS elevated by 2.6 SDs; incidence = 51.8%). Conclusions and Relevance This proof-of-concept suggests that global SZ PRS, sex, and their interaction are robust predictors of risk and that males have a lower PRS threshold for onset. Implications for the integration of these metrics with psychometrically-identified risk are discussed.

Shared vulnerability and sex-dependent polygenic burden in psychotic disorders

Sex-specific association between schizophrenia polygenic risk and subclinical schizophrenia-related traits

Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders

Polygenic Burden Analysis of Longitudinal Clusters of Psychopathological Features in A Cross-Diagnostic Group of Individuals with Severe Mental Illness

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

Shared polygenic susceptibility to treatment response in severe affective and psychotic disorders: Evidence from GWAS data sets

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis

Familial aggregation and shared genetic loading for major psychiatric disorders and type 2 diabetes

Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls

Genetic risk for bipolar disorder and schizophrenia predicts structure and function of the ventromedial prefrontal cortex

Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis

Disentangling heterogeneity in substance use disorder: Insights from genome-wide polygenic scores

Polygenic Risk Scores and Twin Concordance for Schizophrenia and Bipolar Disorder

Characterising the shared genetic determinants of bipolar disorder, schizophrenia and risk-taking

Genome-wide approaches to schizophrenia

Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study

Proof of concept: Molecular prediction of schizophrenia risk

Association of polygenic liabilities for schizophrenia and bipolar disorder with educational attainment and cognitive aging

Depressive Symptoms Evaluated by the Calgary Depression Scale for Schizophrenia (CDSS): Genetic Vulnerability and Sex Effects

Genetic analyses point to alterations in immune-related pathways underpinning the association between psychiatric disorders and COVID-19